Home LiteratureArticle Details
PMID: 20627830 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

The epigenetics of breast cancer.

Molecular oncology ·Vol. 4 ·No. 3 ·2010-06-00 ·Pages 242-54

Jovanovic J, Rønneberg JA, Tost J, Kristensen V

Abstract

Epigenetic changes can be defined as stable molecular alterations of a cellular phenotype such as the gene expression profile of a cell that are heritable during somatic cell divisions (and sometimes germ line transmissions) but do not involve changes of the DNA sequence itself. Epigenetic phenomena are mediated by several molecular mechanisms comprising histone modifications, polycomb/trithorax protein complexes, small non-coding or antisense RNAs and DNA methylation. These different modifications are closely interconnected. Epigenetic regulation is critical in normal growth and development and closely conditions the transcriptional potential of genes. Epigenetic mechanisms convey genomic adaption to an environment thereby ultimately contributing towards given phenotype. In this review we will describe the various aspects of epigenetics and in particular DNA methylation in breast carcinogenesis and their potential application for diagnosis, prognosis and treatment decision.

MeSH Terms
Biomarkers, Tumor/metabolism Breast Neoplasms/diagnosis,genetics,pathology,therapy Chromatin/chemistry,metabolism DNA/chemistry,metabolism DNA Methylation DNA Modification Methylases/metabolism Epigenesis, Genetic Female Gene Expression Regulation, Neoplastic Histones/metabolism Humans MicroRNAs/genetics,metabolism Molecular Structure Prognosis Receptors, Estrogen/genetics,metabolism
Chemicals
Biomarkers, Tumor Chromatin Histones MicroRNAs Receptors, Estrogen DNA DNA Modification Methylases
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Jovanovic Jovana
Department for Clinical Molecular Biology (EpiGen), Institute for Clinical Medicine, Akershus University Hospital, University of Oslo, Norway.
Rønneberg Jo Anders
Tost Jörg
Kristensen Vessela
References (121)
121 references, click to expand
  1. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells.
    Mol Cell Biol. 2004 Jun;24(11):4781-90 PMID: 15143172
  2. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
    J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 PMID: 10749912
  3. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.
    Nat Genet. 2000 Jul;25(3):338-42 PMID: 10888886
  4. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.
    Biochem J. 1999 Sep 1;342 ( Pt 2):249-68 PMID: 10455009
  5. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
    Breast Cancer Res Treat. 2010 Apr;120(3):581-92 PMID: 19459041
  6. DNA methylation in serum of breast cancer patients: an independent prognostic marker.
    Cancer Res. 2003 Nov 15;63(22):7641-5 PMID: 14633683
  7. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
    Cancer Chemother Pharmacol. 2006 Nov;58(5):618-25 PMID: 16783580
  8. Hypermethylation in histologically distinct classes of breast cancer.
    Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5998-6005 PMID: 15447983
  9. Methylation of the BRCA1 gene in sporadic breast cancer.
    Cancer Res. 1997 Aug 15;57(16):3347-50 PMID: 9269993
  10. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13.
    Cancer Res. 2000 Jun 1;60(11):2764-9 PMID: 10850410
  11. Biomarkers for early detection of breast cancer: what, when, and where?
    Biochim Biophys Acta. 2007 Jun;1770(6):847-56 PMID: 17368950
  12. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
    J Biol Chem. 2004 Jan 9;279(2):1562-9 PMID: 14581478
  13. Methylated genes as new cancer biomarkers.
    Eur J Cancer. 2009 Feb;45(3):335-46 PMID: 19138839
  14. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
    Nat Rev Cancer. 2006 Feb;6(2):107-16 PMID: 16491070
  15. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
    Nature. 1998 May 28;393(6683):386-9 PMID: 9620804
  16. Hypermethylation of the Estrogen Receptor Alpha Gene Is Not Related to Lack of Receptor Protein in Human Breast Cancer.
    Breast Cancer. 1999 Apr 25;6(2):79-86 PMID: 11091697
  17. Anticancer activities of histone deacetylase inhibitors.
    Nat Rev Drug Discov. 2006 Sep;5(9):769-84 PMID: 16955068
  18. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Cancer Res. 2003 Jul 15;63(14):4174-80 PMID: 12874023
  19. Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines.
    Genome Res. 2008 May;18(5):791-801 PMID: 18256232
  20. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
    Cancer Res. 2001 Mar 15;61(6):2782-7 PMID: 11289162
  21. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer.
    Br J Cancer. 2009 May 19;100(10):1687-96 PMID: 19436308
  22. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
    J Biol Chem. 2004 Jul 23;279(30):31735-44 PMID: 15150277
  23. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.
    Nat Genet. 1998 Jun;19(2):187-91 PMID: 9620779
  24. Histone acetyltransferases.
    Annu Rev Biochem. 2001;70:81-120 PMID: 11395403
  25. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells.
    Breast Cancer Res. 2005;7(5):R634-44 PMID: 16168108
  26. Mutational spectra of human cancer.
    Hum Genet. 2009 Jun;125(5-6):493-506 PMID: 19308457
  27. An epigenetic road map for histone lysine methylation.
    J Cell Sci. 2003 Jun 1;116(Pt 11):2117-24 PMID: 12730288
  28. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma.
    Cancer Res. 1993 Aug 1;53(15):3472-4 PMID: 8339250
  29. Identification and characterization of the murine ortholog (brms1) of breast-cancer metastasis suppressor 1 (BRMS1).
    Int J Cancer. 2002 Jan 1;97(1):15-20 PMID: 11774238
  30. A role for poly(ADP-ribosyl)ation in DNA methylation.
    Biochem Cell Biol. 2003 Jun;81(3):197-208 PMID: 12897854
  31. Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
    Mol Cell Biol. 2006 Dec;26(23):8683-96 PMID: 17000776
  32. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases.
    J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8 PMID: 15592684
  33. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes.
    Nature. 2001 Feb 1;409(6820):633-7 PMID: 11214324
  34. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression.
    Cancer Res. 1995 Jun 1;55(11):2279-83 PMID: 7538900
  35. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
    Cancer Lett. 2009 Aug 8;280(2):184-91 PMID: 19185986
  36. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.
    Hum Mol Genet. 2001 Dec 15;10(26):3001-7 PMID: 11751682
  37. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
    Clin Cancer Res. 2006 Nov 1;12(21):6410-4 PMID: 17085653
  38. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  39. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
    Cancer Res. 2006 Dec 15;66(24):11954-66 PMID: 17178894
  40. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid.
    Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3306-10 PMID: 16740751
  41. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
    Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 PMID: 11481438
  42. Covalent modifications of histones during mitosis and meiosis.
    Cell Cycle. 2009 Nov 15;8(22):3688-94 PMID: 19855177
  43. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
    Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):28-32 PMID: 14734448
  44. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer.
    Clin Cancer Res. 2008 Jun 1;14(11):3494-502 PMID: 18519782
  45. Array-based multiplex analysis of DNA methylation in breast cancer tissues.
    J Mol Diagn. 2008 Jan;10(1):93-101 PMID: 18165279
  46. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
    Cancer Lett. 2006 Jan 8;231(1):87-93 PMID: 16356834
  47. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
    Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):87-92 PMID: 11134513
  48. Histone acetylation and an epigenetic code.
    Bioessays. 2000 Sep;22(9):836-45 PMID: 10944586
  49. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
    Cancer Res. 2001 Apr 1;61(7):3105-9 PMID: 11306494
  50. Gene expression profiling of peripheral blood cells for early detection of breast cancer.
    Breast Cancer Res. 2010;12(1):R7 PMID: 20078854
  51. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
    Clin Cancer Res. 2005 Aug 15;11(16):5869-77 PMID: 16115928
  52. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer.
    J Natl Cancer Inst. 2000 May 17;92(10):826-32 PMID: 10814678
  53. The epigenomics of cancer.
    Cell. 2007 Feb 23;128(4):683-92 PMID: 17320506
  54. Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus.
    Science. 2001 Sep 28;293(5539):2453-5 PMID: 11498546
  55. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin.
    J Biol Chem. 2001 Aug 24;276(34):32282-7 PMID: 11427539
  56. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Clin Cancer Res. 2009 Jan 1;15(1):315-23 PMID: 19118060
  57. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer.
    Oncol Rep. 2008 Mar;19(3):663-8 PMID: 18288399
  58. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Cancer Res. 2003 Feb 1;63(3):664-73 PMID: 12566312
  59. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1.
    Exp Cell Res. 2002 Feb 15;273(2):229-39 PMID: 11822878
  60. Cell type-specific DNA methylation patterns in the human breast.
    Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14076-81 PMID: 18780791
  61. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.
    Cancer Res. 1995 Nov 15;55(22):5195-9 PMID: 7585573
  62. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
    Breast Cancer Res. 2007;9(4):R57 PMID: 17764565
  63. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.
    Mol Cell Biol. 2000 Sep;20(18):6891-903 PMID: 10958685
  64. Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone.
    Biochem Biophys Res Commun. 2006 Oct 6;348(4):1429-35 PMID: 16919237
  65. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.
    Hum Mol Genet. 2001 Apr;10(7):693-8 PMID: 11257101
  66. Analysis of mechanisms underlying BRMS1 suppression of metastasis.
    Clin Exp Metastasis. 2000;18(8):683-93 PMID: 11827072
  67. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression.
    Annu Rev Biochem. 2006;75:243-69 PMID: 16756492
  68. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
    Breast Cancer Res. 2010;12(1):R3 PMID: 20056007
  69. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype.
    Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):710-5 PMID: 10639144
  70. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells.
    Cancer Res. 1998 Aug 15;58(16):3508-12 PMID: 9721850
  71. Histone methylation in transcriptional control.
    Curr Opin Genet Dev. 2002 Apr;12(2):198-209 PMID: 11893494
  72. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
    Cancer Res. 1995 Oct 15;55(20):4525-30 PMID: 7553621
  73. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.
    Cancer Res. 2005 May 1;65(9):3586-95 PMID: 15867352
  74. Regulation of chromatin structure by site-specific histone H3 methyltransferases.
    Nature. 2000 Aug 10;406(6796):593-9 PMID: 10949293
  75. DNA methylation and breast carcinogenesis.
    Oncogene. 2002 Aug 12;21(35):5462-82 PMID: 12154408
  76. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
    Mol Cancer Ther. 2007 Mar;6(3):1089-98 PMID: 17363502
  77. Breast cancer epigenetics: normal human mammary epithelial cells as a model system.
    J Mol Med (Berl). 2008 Dec;86(12):1315-28 PMID: 18716754
  78. Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers.
    Mol Cancer Res. 2008 Nov;6(11):1710-7 PMID: 19010819
  79. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
    Eur J Cancer. 2007 Jul;43(11):1679-86 PMID: 17601725
  80. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic.
    Clin Cancer Res. 1995 Jul;1(7):677-86 PMID: 9816032
  81. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  82. Agglomerative epigenetic aberrations are a common event in human breast cancer.
    Cancer Res. 2008 Oct 15;68(20):8616-25 PMID: 18922938
  83. Emerging treatment combinations: integrating therapy into clinical practice.
    Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S9-S14 PMID: 19923318
  84. The language of covalent histone modifications.
    Nature. 2000 Jan 6;403(6765):41-5 PMID: 10638745
  85. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2008 Oct;111(3):429-37 PMID: 17965955
  86. Epigenomics and breast cancer.
    Pharmacogenomics. 2008 Dec;9(12):1879-902 PMID: 19072646
  87. Regional copy number-independent deregulation of transcription in cancer.
    Nat Genet. 2006 Dec;38(12):1386-96 PMID: 17099711
  88. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
    Nat Genet. 2000 Jul;25(3):315-9 PMID: 10888881
  89. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
    Int J Cancer. 2003 Dec 20;107(6):970-5 PMID: 14601057
  90. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy.
    Trends Pharmacol Sci. 2004 Nov;25(11):551-4 PMID: 15491775
  91. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR.
    Lancet. 2001 Apr 28;357(9265):1335-6 PMID: 11343741
  92. BRCA1 dysfunction in sporadic basal-like breast cancer.
    Oncogene. 2007 Mar 29;26(14):2126-32 PMID: 17016441
  93. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication.
    Cancer Res. 2001 Mar 1;61(5):1765-7 PMID: 11280719
  94. HIN-1, an inhibitor of cell growth, invasion, and AKT activation.
    Cancer Res. 2005 Nov 1;65(21):9659-69 PMID: 16266985
  95. The epigenetics of breast cancer.
    Mol Oncol. 2010 Jun;4(3):242-54 PMID: 20627830
  96. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin.
    Nat Genet. 2002 Jan;30(1):77-80 PMID: 11740497
  97. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote.
    Genes Dev. 2004 Jun 1;18(11):1263-71 PMID: 15175259
  98. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.
    Cancer Res. 2005 Feb 15;65(4):1141-5 PMID: 15734995
  99. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band.
    Nat Genet. 2006 May;38(5):540-9 PMID: 16642018
  100. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation.
    Mol Cancer. 2007 Jan 16;6:6 PMID: 17227585
  101. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
    Oncogene. 1998 Mar 5;16(9):1161-9 PMID: 9528858
  102. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.
    Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3036-43 PMID: 19861523
  103. Cancer epigenomics: DNA methylomes and histone-modification maps.
    Nat Rev Genet. 2007 Apr;8(4):286-98 PMID: 17339880
  104. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
    Mol Cancer. 2010 Mar 25;9:68 PMID: 20338046
  105. Detection of gene promoter hypermethylation in fine needle washings from breast lesions.
    Clin Cancer Res. 2003 Aug 15;9(9):3413-7 PMID: 12960130
  106. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia.
    Cancer Res. 2003 Apr 1;63(7):1596-601 PMID: 12670910
  107. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world.
    Bioessays. 2001 Sep;23(9):820-30 PMID: 11536294
  108. Epigenetic regulation as a new target for breast cancer therapy.
    Cancer Invest. 2007 Dec;25(8):659-65 PMID: 18058459
  109. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.
    Clin Cancer Res. 1996 May;2(5):805-10 PMID: 9816234
  110. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
    Cancer Res. 2005 May 15;65(10):4101-17 PMID: 15899800
  111. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  112. Quantitative assessment of promoter hypermethylation during breast cancer development.
    Am J Pathol. 2002 Feb;160(2):605-12 PMID: 11839581
  113. Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.
    Clin Exp Metastasis. 2008;25(7):753-63 PMID: 18566899
  114. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.
    Cancer Res. 2004 Jun 1;64(11):3807-13 PMID: 15172987
  115. DNA methylation patterns and epigenetic memory.
    Genes Dev. 2002 Jan 1;16(1):6-21 PMID: 11782440
  116. Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells.
    Cancer Res. 2005 Feb 1;65(3):713-7 PMID: 15705865
  117. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
    Br J Cancer. 2009 Oct 6;101(7):1044-50 PMID: 19738609
  118. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
    J Clin Oncol. 2006 Sep 10;24(26):4262-9 PMID: 16908936
  119. The diverse functions of histone lysine methylation.
    Nat Rev Mol Cell Biol. 2005 Nov;6(11):838-49 PMID: 16261189
  120. Epigenetic inactivation of the HOXA gene cluster in breast cancer.
    Cancer Res. 2006 Nov 15;66(22):10664-70 PMID: 17090521
  121. Histone deacetylase inhibitors for cancer therapy.
    Epigenetics. 2006 Jan-Mar;1(1):14-23 PMID: 17998811
Article Info
Journal
Molecular oncology
Abbr.
Mol Oncol
ISSN
1878-0261
DOI
10.1016/j.molonc.2010.04.002
Published
2010-06-00
Epub
2010-00-29
Pages
242-54
Language
English
Region
United States
NLM ID
101308230
PMCID
PMC5527941
Subset
IM
External Links
PubMed source DOI: 10.1016/j.molonc.2010.04.002 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2